Overview

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.
Phase:
Phase 1
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Melphalan
Vidarabine